Skip to main content
. 2018 May 7;8:142. doi: 10.3389/fonc.2018.00142

Figure 4.

Figure 4

Effects of carmustine [bis-chloroethylnitrosourea (BCNU)] and leucine-rich repeat-containing 8A (LRRC8A) siRNA viability and proliferation of glioblastoma (GBM) cells determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (A) or Coulter counter (B) assays. GBM cells were transfected with siLRRC8A_3 (siA_3) or negative control siRNA (siNC). 48 h post-transfection cells were additionally treated with 167 µM BCNU. Relative levels of cell proliferation were determined 48 h after addition of BCNU (96 h post-transfection with siRNA) using an MTT assay. Non-transfected cells (NTF) were used as an additional internal control in MTT experiments. The data are the mean values ± SE of three independent experiments performed in triplicates (n = 3) in MTT assays, or four independent transfections (n = 4) in Coulter counter experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. cells transfected with siNC. p < 0.05, ¶¶p < 0.01, ¶¶¶p < 0.001, within the group effect of BCNU vs. siRNA or mock treatment alone. #p < 0.05, ###p < 0.001, BCNU effect in cells treated with siNC vs. cells treated with siLRRC8A_3.